CSRxP APPLAUDS U.S. HOUSE PASSAGE OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION IN THE PRESCRIPTION DRUG MARKETPLACE
Dec 2, 2025
Bipartisan, Market-Based Solution Would Increase Transparency… Read More
© 2026 CSRXP- All Rights Reserved
Statements
CSRxP APPLAUDS ADMINISTRATION FOR COMMITMENT TO FOSTERING GREATER BIOSIMILAR COMPETITION, LOWERING DRUG PRICES FOR AMERICAN PATIENTS
Oct 29, 2025
Efforts to Eliminate Red Tape and Boost Access to More Affordable Alternatives… Read More
CSRxP: HELP COMMITTEE SHOULD REJECT BIG PHARMA’S DEBUNKED INNOVATION RHETORIC, FOCUS ON IMPROVING COMPETITION TO HIGH-PRICED BIOLOGIC BLOCKBUSTERS
Oct 28, 2025
Lawmakers Can Add to Bipartisan Momentum for Market-Based Solutions to Foster… Read More
CSRxP: PERA WOULD FURTHER ENABLE BIG PHARMA’S PATENT ABUSE THAT KEEPS PRESCRIPTION DRUG PRICES HIGH
Oct 7, 2025
Senate Judiciary Lawmakers Should Reject Big Pharma-Backed Proposal and… Read More
U.S. HOUSE COMMITTEE SHOULD ADVANCE Q1/Q2 REFORMS TO PROMOTE GREATER COMPETITION AND HELP LOWER PRESCRIPTION DRUG PRICES
Sep 17, 2025
Lawmakers Should Advance Bipartisan, Market-Based Solution to Crack Down on… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO HIGHLIGHT BIG PHARMA’S EGREGIOUS PRICING AND ANTI-COMPETITIVE PRACTICES IN HEARING ON HEALTH CARE AFFORDABILITY
Jul 30, 2025
Lawmakers Can Build on Track Record of Bipartisan Collaboration by Advancing… Read More
CSRxP STATEMENT ON U.S. SENATE REINTRODUCTION OF THE ETHIC ACT
Jul 16, 2025
Coalition Commends Bipartisan Group of Lawmakers for Commitment to Cracking… Read More
CSRxP STATEMENT ON BIG PHARMA GIVEAWAY IN RECONCILIATION BILL TEXT
Jun 28, 2025
Pharma-Backed Policy Would Cost Seniors and Taxpayers Billions of Dollars in… Read More
CSRxP APPLAUDS U.S. SENATE REINTRODUCTION OF BIPARTISAN SOLUTION TO PROMOTE GREATER BIOSIMILAR COMPETITION IN THE PRESCRIPTION DRUG MARKET
Jun 6, 2025
Legislation Would Remove Regulatory Barriers to Foster Greater Competition… Read More
CSRxP COMMENDS ADMINISTRATION FOR CHALLENGING MORE THAN 200 OF BIG PHARMA’S SHAM PATENTS THAT BLOCK COMPETITION AND KEEP DRUG PRICES HIGH
May 27, 2025
FTC’s Continued Crackdown on Bogus Patents Listed in the Orange Book Will… Read More
CSRxP STATEMENT ON PRESIDENT TRUMP’S MOST FAVORED NATION EXECUTIVE ORDER
May 13, 2025
Administration Rightly Diagnoses Big Pharma’s Egregious Pricing Practices as… Read More
CSRxP: PHARMA-BACKED PERA AND PREVAIL ACT WOULD FURTHER ENABLE PATENT ABUSE, UNDERMINE BIPARTISAN PROGRESS TOWARD GREATER COMPETITION
May 1, 2025
Lawmakers Should Focus on Market-Based Solutions That Hold Big Pharma… Read More